9. Genotype 1: Standard Treatment

  1. Geoffrey W. McCaughan MBBS, PhD, FRACP2,3,
  2. John G. McHutchison MD4 and
  3. Jean-Michel Pawlotsky MD, PhD5,6
  1. Rebekah G. Gross MD and
  2. Ira M. Jacobson MD

Published Online: 3 NOV 2011

DOI: 10.1002/9781444346343.ch9

Advanced Therapy for Hepatitis C

Advanced Therapy for Hepatitis C

How to Cite

Gross, R. G. and Jacobson, I. M. (2011) Genotype 1: Standard Treatment, in Advanced Therapy for Hepatitis C (eds G. W. McCaughan, J. G. McHutchison and J.-M. Pawlotsky), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444346343.ch9

Editor Information

  1. 2

    Centenary Research Institute, Sydney, NSW, Australia

  2. 3

    Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia

  3. 4

    Liver Disease Therapeutics, Gilead Sciences, Inc., Foster City, CA, USA

  4. 5

    French National Reference Center for Viral Hepatitis B, C and delta, Créteil, France

  5. 6

    Department of Virology, Bacteriology, and Hygiene, INSERM U955, Hôpital Henri Mondor, Université Paris Est, Créteil, France

Author Information

  1. Division of Gastroenterology and Hepatology, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, USA

Publication History

  1. Published Online: 3 NOV 2011
  2. Published Print: 24 NOV 2011

ISBN Information

Print ISBN: 9781405187459

Online ISBN: 9781444346343



  • hepatitis C;
  • peginterferon;
  • interferon;
  • ribavirin;
  • genotype 1;
  • standard of care


In the 20 years since publication of the original trials investigating the use of interferon for chronic hepatitis C, the treatment algorithm has been refined significantly. Notable advances have included pegylation of the interferon molecule and addition of ribavirin to the regimen, changes that have increased the efficacy of treatment. Still, among patients with genotype 1 infection, only 40–50% who undergo a 48-week-long course of therapy achieve a sustained viral response (SVR). Advances in therapy are on the horizon, with agents in development that should enable more patients to achieve positive outcomes. As monotherapy, these agents promote resistance. Consequently, it is expected that they will be prescribed in combination with the current treatment regimen. Interferon and ribavirin are thus poised to remain the cornerstones of hepatitis C therapy in the years to come. This chapter reviews the literature informing the use of pegylated interferon and ribavirin in the standard of care protocol for the genotype 1 population, with a focus on dosing medication and monitoring response to treatment.